Commercializing the Next Frontier of Targeted Science in Oncology

Session details:

• Redefining “Care:” Why moving past incremental gains toward novel therapeutic classes (such as targeted protein degradation) is essential to improving patient depth of response and long-term outcomes.
• The Innovation-Access Continuum: How commercial agility and early value demonstration ensure that complex, next-generation platforms navigate health systems swiftly to reach patients without delay.
• Partnering at the Frontlines of Care: Supporting oncologists and multidisciplinary teams as treatment decisions become increasingly complex, ensuring breakthroughs integrate into everyday clinical practice.